Impact of Hyperglycemia on Outcomes among Patients Receiving Neoadjuvant Chemotherapy for Bulky Early Stage Cervical Cancer

Jing Li¹,²*, Miao-fang Wu¹*, Huai-wu Lu¹, Bing-zhong Zhang¹, Li-juan Wang¹*, Zhong-qiu Lin¹*

¹ Department of Gynecologic Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China, ² Team-based Learning Group of Clinical Study, Sun Yat-sen University, Guangzhou, People’s Republic of China

* These authors contributed equally to this work.
* wanglijuan_sysu@sina.com (LJW); zhongqiu_lin@163.com (ZQL)

Abstract

Background

The impact of hyperglycemia on survival of patients undergoing neoadjuvant chemotherapy (NACT) for bulky early stage cervical cancer (BESCC) has not been explored.

Method

Records of patients who received NACT and radical hysterectomy in our institution between January 2005 and June 2010 were reviewed.

Results

In total, 347 patients were included. The median follow-up time was 37 months (range: 4–65). Patients with hyperglycemia (fasting blood glucose ≥ 100 mg/dl) had shorter recurrence-free survival (RFS) (univariate hazard ratio [HR] = 1.95, 95% confidence interval [CI] [1.16, 3.28], P = 0.010) and cancer-specific survival (CSS) (univariate HR = 2.24, 95% CI [1.33, 3.78], P = 0.002) compared with those with euglycemia (fasting blood glucose <100 mg/dl). In multivariate analysis, positive surgical margins, parametrium invasion, node metastasis, hyperglycemia and complete response to NACT independently predicted recurrence and cancer-specific death. To further validate the prognostic value of hyperglycemia, we conducted a subgroup analysis based on patient baseline characteristics and prognostic effect of hyperglycemia remained significant in all subgroups. On multivariable logistic regression analysis, euglycemia before NACT, squamous cell tumor and pre-treatment squamous cell carcinoma antigen levels < 3.5 ng/ml were identified as independent predictors of complete response after NACT.

Conclusions

FBG ≥100 mg/dl is a negative prognostic predictor for cervical cancer patients receiving NACT for BESCC. Patients with hyperglycemia are less likely to achieve complete response.
after NACT. Our findings underscore the clinical utility of hyperglycemia screening of for cervical cancer patients.

Background

Cervical cancer is the leading cause of cancer-related death for women in developing countries [1]. Because a well-organized, nation-wide screening system has not been established in most developing countries, cervical cancer always cannot be detected at an early stage or in a pre-cancerous situation [2]. In fact, 70% of new cases in these countries are diagnosed at an advanced stage [3]. For patients with bulky early stage cervical cancer (BESCC), concurrent chemoradiotherapy (CCRT) has been the primary treatment [1]. Although excellent tumor control can be achieved after CCRT, impaired quality of life due to radiation-induced ovarian failure and vaginal fibrosis is significant [4]. Furthermore, in developing countries, radiotherapy facilities are not always readily available [5]. Against this background, neoadjuvant chemotherapy (NACT) combined with radical hysterectomy has been proposed as a possible alternative to CCRT. NACT can decrease tumor size, eliminate subclinical lesions and decrease the risk of lymph node metastasis thereby minimizing the need for postsurgical radiotherapy [6–9]. Because of these advantages, NACT is used in up to 25% of cervical cancer patients in many parts of the world such as Asia, Italy and South America [10].

In recent clinical studies, significant poor survival has been observed in cancer patients with elevated blood glucose levels [11–22]. Of these studies, three enrolled patients with cervical cancer [18, 19, 22]. However, patients included in these studies did not receive NACT and their baseline characteristics varied significantly with regard to tumor stage and treatment modality. Additionally, potential confounders such as obesity and dyslipidemia were not accounted for in these studies. Because there are difficulties in the interpretation of the results and no data has supported the use of plasma glucose as a prognostic factor for BESCC patients receiving NACT to date, we designed a retrospective cohort study to investigate whether elevated levels of fasting blood glucose (FBG) levels impact the prognosis of patients with BESCC.

Materials and Methods

Patients

After approval from the Sun Yat-sen Memorial Hospital Institutional Review Board was obtained, we reviewed the medical records of patients who received NACT and subsequent class III radical hysterectomy for cervical cancer from our institution between January 2005 and June 2010. Inclusion criteria were as follows: histologically confirmed squamous cell carcinoma and adenocarcinoma, FIGO (Federation International of Gynecology and Obstetrics) stage IB2 and IIA2 disease, age ≥ 16 years and signed informed consent provided. Exclusion criteria were as follows: patients receiving any treatment at other institutions and patients with a history of previous chemotherapy or radiation therapy or a history of other types of malignancies. For patients included in the present study, related data were abstracted including the clinical notes, operative notes, histopathologic reports and follow-up notes.

Pretreatment evaluation consisted of a complete physical and gynecologic examination, chest radiography, pelvic ultrasonography and laboratory tests. Gynecologic examination was performed by at least two senior gynecologists. Tumors were classified according to the FIGO...
staging system. All cervical pathology was reviewed by at least two authorized pathologists from our institution.

All patients received 2–3 cycles of NACT, and the chemotherapeutic regimens were as follows: TP, paclitaxel + cisplatin; FP, 5-fluouracil + cisplatin; TC, paclitaxel + carboplatin; BVP, bleomycin + vincristine + cisplatin. Type III radical hysterectomy with pelvic lymphadenectomy was performed within four weeks after the last cycle of chemotherapy. Pathological responses were retrospectively evaluated and complete response (CR) was defined as no evidence of viable tumor cells on the tumorous area [23]. CCRT was prescribed to patients with risk factors including positive parametrium, positive lymph nodes, involved surgical margins, greater than one-third stromal invasion and lymphatic vascular space involvement [1]. Adjuvant chemotherapy was given at the discretion of the treating gynecologist. Blood samples were collected for laboratory tests within one week before initiation of NACT, and fasting is defined as no caloric intake for at least eight hours. FBG was measured using a glucose oxidase assay (Tosoh Corp., Tosoh, Japan). Serum triglyceride (TG), total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were assessed enzymatically with commercially available reagents (Hitachi automatic biochemical analyzer model 7170, Hitachi, Tokyo, Japan). Chinese diagnosis criteria for dyslipidemia were used to classify patients into normal and abnormal groups [24]. Serum squamous cell carcinoma antigen (SCCA) was assessed with an immunoradiometric assay kit (Imx, Abbott Diagnostics, Abbott Park, IL, USA). A cutoff value of 3.5 ng/ml was used to stratify patients into normal and abnormal groups [25]. The intra-assay variation was < 9% for all variables measured. According to American Diabetes Association (ADA) criteria, patients were classified into a euglycemic group (UG group, FBG < 100 mg/dl) and a hyperglycemic group (HG group, FBG ≥ 100 mg/dl). Diabetes mellitus (DM) was diagnosed if FBG levels ≥ 126 mg/dl [26].

Patients underwent routine follow-up every 3 months for 2 years after the completion of therapy, every 6 months for the subsequent 3 years and annually thereafter. At each follow-up visit, complete history and physical examination and Papanicolaou smear of the vaginal vault were performed. Follow-up information was obtained from office visits or telephone interviews. Tumor recurrence was diagnosed by biopsy or imaging methods including positron emission tomography-computed tomography (PET-CT), magnetic resonance imaging (MRI) and computed tomography (CT).

Statistical Analyses

The primary aim of the current study was to assess the influence of hyperglycemia on cancer recurrence and cancer-specific death. Recurrence-free survival (RFS) and cervical cancer-specific survival (CSS) were measured from the date of NACT until the date of events (recurrence or death from cervical cancer) or the date of last follow-up. The Kolmogorov-Smirnov test was used to determine the distribution of continuous variables. Student’s t test was used to compare normally distributed continuous variables, whereas the Mann-Whitney U test was used for data with non-normal distributions. The Chi-square test ($\chi^2$) or Fisher’s exact test were used to analyze the frequency distribution between categorical variables where appropriate. RFS and CSS were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazard models in a forward stepwise method (conditional logistic regression) were utilized to assess the association between clinical and pathological variables and RFS and CSS. Significant variables ($P < 0.05$) in the univariate analysis were entered into multivariate analysis. To determine independent predictors for CR, a binary logistic regression model was used and variables with significance at $P < 0.05$ in the univariable analysis were
considered as candidates in the final model. Statistical tests were two-sided and a $P$ value $< 0.05$ was considered to be statistically significant. All analysis was performed using IBM SPSS (version 13.0, SPSS, Chicago, IL, USA).

**Results**

**Characteristics of the study population**

In total, 347 patients were included, and elevated levels of FBG were observed in 72 patients (20.7%). Clinicopathologic characteristics are summarized in Table 1. The median FBG was 91.1 mg/dl (range: 71.4–98.2) and 110.7 mg/dl (range: 100.0–180.4) in the UG and HG groups, respectively. Of the 72 patients in the HG group, 16 (22.2%) had DM. Only 5 of these 16 (31.3%) patients were diagnosed with DM before they were referred to our institution. The HG group had significantly more women with hypertension, heart disease and lower levels of HDL, whereas the UG group had more patients achieving CR after NACT. Additionally, adjuvant chemotherapy and NACT consisting of cisplatin and paclitaxel were more frequently prescribed to UG patients.

**Factors associated with CR after NACT**

Given the importance of response to NACT, we conducted regression analysis to detect independent factors associated with CR after NACT. The results are summarized in Table 2. Of the variables of interest, euglycemia before NACT, squamous cell tumor and pre-treatment SCCA levels $< 3.5$ ng/ml were significantly associated with CR after NACT on univariate analysis. Furthermore, these two factors were identified as independent predictors of CR on multivariate analysis.

**Survival analysis**

The median follow-up time was 37 months (range: 4–65). Recurrence was documented in 44 (16.0%) patients in the UG group and 21 (29.2%) in the HG group, respectively. Of the 65 patients, extra-pelvic lesion was noted in 34 (52.3%) patients, pelvic lesion was noted in 19 (29.2%) patients and mixed lesion (extra-pelvic + pelvic) lesion was noted in 12 (18.5%) patients. Cancer-specific death was noted in 39 (14.2%) patients in the UG group and 22 (30.6%) patients in the HG group, respectively. Compared with the UG patients, the hazard of recurrence (univariate hazard ratio [HR] = 1.95, 95% CI [1.16, 3.28], $P = 0.010$; Fig 1) was significantly higher in the HG patients. To investigate whether there is a link between hyperglycemia and distant recurrence, we did an additionally analysis. We noted a trend that hyperglycemia was associated with increased risk of extra-pelvic recurrence. However, this did not reach statistical significance (HR = 1.62, 95% CI [0.85, 3.07]; $P = 0.143$). Compared with the UG patients, the risk of cancer-specific death (univariate HR = 2.24, 95% CI [1.33, 3.78], $P = 0.002$; Fig 2) was significantly higher in the HG patients.

The Cox proportional hazard model was used to identify variables that were associated with RFS (Table 3) and CSS (Table 4). On univariate analysis, tumor histology, lymphatic vascular space involvement (LVSI), surgical margin, lymph node involvement, parametrium invasion, CR after NACT, FBG and the utility of CCRT were significant predictors for RFS. On multivariate analysis, positive surgical margins, parametrium invasion, node metastasis, hyperglycemia and CR were independent prognostic factors for RFS. Univariate analysis showed that tumor histology, positive nodes, positive surgical margins, positive parametrium, SCCA, hyperglycemia, utility of CCRT and CR after NACT were associated with CSS. In the multivariate model, tumor histology, CCRT and SCCA were not independently associated with CSS.
Table 1. Patient Baseline Demographic and Clinical Characteristics.

|                                | Euglycemia (n = 275) | Hyperglycemia (n = 72) | P value |
|--------------------------------|----------------------|------------------------|---------|
| Age (years), median (range)    | 52 (24–80)           | 50 (26–72)             | 0.412   |
| Diagnosis of DM, n (%)         |                      |                        |         |
| Yes                            | 0                    | 16 (22.2)              |         |
| No                             | 0                    | 56 (77.8)              |         |
| BMI (kg/m²), n (%)             |                      |                        |         |
| <25                            | 240 (87.3)           | 57 (79.2)              | 0.081   |
| ≥25                            | 35 (12.7)            | 15 (20.8)              |         |
| Smoking, n (%)                 |                      |                        |         |
| Never                          | 261 (94.9)           | 66 (91.7)              | 0.634   |
| Former                         | 6 (2.2)              | 3 (4.2)                |         |
| Current                        | 1 (0.4)              | 0 (0)                  |         |
| Missing data                   | 7 (2.5)              | 3 (4.2)                |         |
| Regular cervical cancer screening, n (%) |           |                        |         |
| Yes                            | 14 (5.1)             | 9 (12.5)               | 0.112   |
| No                             | 240 (87.3)           | 58 (80.6)              |         |
| Missing data                   | 21 (7.6)             | 5 (6.9)                |         |
| SCCA (ng/ml), n (%)            |                      |                        |         |
| ≥3.5                           | 162 (58.9)           | 39 (54.2)              | 0.468   |
| <3.5                           | 113 (41.1)           | 33 (45.8)              |         |
| Stage, n (%)                   |                      |                        |         |
| IB2                            | 142 (51.6)           | 34 (47.2)              | 0.505   |
| IIA2                           | 133 (48.4)           | 38 (52.8)              |         |
| Tumor histology, n (%)         |                      |                        |         |
| SCC                            | 230 (83.6)           | 59 (81.9)              | 0.732   |
| NSCC                           | 45 (16.4)            | 13 (18.1)              |         |
| Hypertension, n (%)            |                      |                        |         |
| Yes                            | 53 (19.3)            | 33 (45.8)              | <0.001  |
| No                             | 222 (80.7)           | 39 (54.2)              |         |
| Heart disease, n (%)           |                      |                        |         |
| Yes                            | 13 (4.7)             | 12 (16.7)              | <0.001  |
| No                             | 262 (95.3)           | 60 (83.3)              |         |
| CHO (mg/dl), n (%)             |                      |                        |         |
| ≥200                           | 124 (45.1)           | 38 (52.8)              | 0.244   |
| <200                           | 151 (54.9)           | 34 (47.2)              |         |
| TG (mg/dl), n (%)              |                      |                        |         |
| ≥150                           | 50 (18.2)            | 19 (26.4)              | 0.120   |
| <150                           | 225 (81.8)           | 33 (45.8)              |         |
| LDL-C (mg/dl), n (%)           |                      |                        |         |
| ≥130                           | 45 (16.4)            | 17 (23.6)              | 0.153   |
| <130                           | 230 (83.6)           | 55 (76.4)              |         |
| HDL-C (mg/dl), n (%)           |                      |                        |         |
| ≥40                            | 260 (94.5)           | 59 (81.9)              | <0.001  |
| <40                            | 15 (5.5)             | 13 (18.1)              |         |
| Differentiation, n (%)         |                      |                        |         |
| 1                              | 147 (53.5)           | 38 (52.8)              | 0.540   |
| 2                              | 95 (34.5)            | 22 (30.6)              |         |
| 3                              | 33 (12.0)            | 12 (16.7)              |         |

(Continued)
A previous history of diabetes might have a great impact on outcomes, so we excluded the 16 cases with a previous history of DM and conducted sensitivity analyses (Table 3 and Table 4). We found that hyperglycemia was associated with decreased RFS (HR = 2.00, 95% CI [1.14, 3.50]; \( P = 0.015 \)) and CSS (HR = 2.31, 95% CI [1.32, 4.03]; \( P = 0.003 \)). After adjustment for other variables, hyperglycemia remained an independent predictor of CSS.

**Subgroup analysis for the effect of hyperglycemia**

Table 5 summarizes the results of subgroup analysis. We noted that the prognostic effect of hyperglycemia remained in the subgroup analyses of age, BMI, tumor stage, tumor histology, tumor differentiation, SCCA, CHOL, TG, LDL-C, HDL-C and the NACT regimens.

The majority of our cohort (88.5%) received TP as the NACT regimen. A further analysis was conducted to explore the prognostic value of hyperglycemia in this patient subgroup. Compared with euglycemic patients, patients with hyperglycemia had significantly higher risk of recurrence (HR = 2.10, 95% CI [1.20, 3.67]; \( P = 0.009 \)) and cancer-specific death (HR = 2.07, 95% CI [1.14, 3.74]; \( P = 0.016 \)).

---

**Table 1. (Continued)**

|                         | Euglycemia (n = 275) | Hyperglycemia (n = 72) | \( P \) value |
|-------------------------|----------------------|------------------------|---------------|
| Deep stromal invasion, n (%) | Yes 230 (83.6) | 56 (77.8) | 0.245 |
|                         | No 45 (16.4) | 16 (22.2) | 0.245 |
| LVSI, n (%)             | Yes 166 (60.4) | 35 (48.6) | 0.072 |
|                         | No 109 (39.6) | 37 (51.4) | 0.072 |
| Positive margins, n (%) | Yes 9 (3.3) | 5 (6.9) | 0.159 |
|                         | No 266 (96.7) | 67 (93.1) | 0.159 |
| Positive nodes, n (%)   | Yes 108 (39.3) | 28 (38.9) | 0.953 |
|                         | No 167 (60.7) | 44 (61.1) | 0.953 |
| Positive parametrium, n (%) | Yes 10 (3.6) | 7 (9.7) | 0.068 |
|                         | No 265 (96.4) | 65 (90.3) | 0.068 |
| Adjuvant chemotherapy, n (%) | Yes 71 (25.8) | 10 (13.9) | 0.033 |
|                         | No 204 (74.2) | 62 (86.1) | 0.033 |
| Post-surgical CCRT, n (%) | Yes 237 (86.2) | 57 (79.2) | 0.141 |
|                         | No 38 (13.8) | 15 (20.8) | 0.141 |
| CR achieved, n (%)      | Yes 77 (28.0) | 10 (13.9) | 0.014 |
|                         | No 198 (72.0) | 62 (86.1) | 0.014 |
| NACT regimen, n (%)     | Cisplatin-paclitaxel 249 (90.5) | 58 (80.6) | 0.018 |
|                         | Cisplatin-based 26 (9.5) | 14 (19.4) | 0.018 |

Abbreviation: BMI, body mass index; CCRT, concurrent chemoradiotherapy; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; SCCA, squamous cell carcinoma antigen; TG, triglyceride

doi:10.1371/journal.pone.0166612.t001
Discussion

Our study showed that FBG ≥ 100 mg/dl was a significant risk factor for recurrence and cancer-specific death. Positive surgical margins, positive nodes, positive parametrium and hyperglycemia were identified as independent prognostic markers for worse RFS and CSS. CR after NACT was independently associated with improved RFS and CSS. The prognostic effect of

Table 2. Univariate and Multivariate Analysis of Factors Associated with Complete Response Following Neoadjuvant Chemotherapy.

|                                | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | OR                  | 95% CI                | P value   | OR                  | 95% CI                | P value   |
| Age (≥60 vs. <60)              | 0.73                | [0.37, 1.44]          | 0.359     |                     |                      |           |
| Histology (non-squamous vs. squamous) | 0.36                | [0.16, 0.82]          | 0.016     | 0.32                | [0.14, 0.74]          | 0.008     |
| Tumor stage (IIA2 vs IB2)      | 0.97                | [0.76, 1.24]          | 0.829     |                     |                      |           |
| Tumor differentiation (G3 vs. G1-2) | 0.96                | [0.47, 1.99]          | 0.917     |                     |                      |           |
| FBG (≥100 mg/dl vs <100 mg/dl) | 0.42                | [0.20, 0.85]          | 0.016     | 0.39                | [0.19, 0.81]          | 0.012     |
| CHO (≥200 mg/dl vs. <200 mg/dl) | 1.09                | [0.67, 1.77]          | 0.731     |                     |                      |           |
| TG (≥150 mg/dl vs. <150 mg/dl) | 0.97                | [0.53, 1.79]          | 0.926     |                     |                      |           |
| LDL-C (≥130 mg/dl vs. <130 mg/dl) | 0.67                | [0.34, 1.33]          | 0.254     |                     |                      |           |
| HDL-C (≥40 mg/dl vs. <40 mg/dl) | 1.00                | [0.41, 2.43]          | 0.993     |                     |                      |           |
| SCCA (≥3.5 ng/mL vs. <3.5 ng/mL) | 0.46                | [0.28, 0.76]          | 0.002     | 0.41                | [0.25, 0.68]          | 0.001     |

Abbreviation: CI, confidence interval; CHO, total cholesterol; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio; SCCA, squamous cell carcinoma antigen; TG, triglyceride

doi:10.1371/journal.pone.0166612.t002

Fig 1. Kaplan–Meier survival curves for recurrence-free survival of cervical cancer patients receiving neoadjuvant chemotherapy for bulky early stage disease. The P values were determined by the log-rank test.

doi:10.1371/journal.pone.0166612.g001
hyperglycemia remained significant in the predefined subgroup analysis. Moreover, hyperglycemic patients were less likely to achieve CR after NACT.

There are three studies evaluating the prognostic value of plasma glucose in cervical cancer patients. Despite this, none of them involved patients treated with NACT and radical surgery. Lee et al. analyzed 134 patients exclusively treated by radiotherapy for FIGO stage IIB-IVA cervical cancer [18]. They reported that patients with glucose levels ≥102 mg/dl had decreased CSS time and progression-free intervals after adjusting for other clinical factors. In the study by Rosekeila et al., levels of plasma glucose were observed to be significantly higher in patients with invasive cervical cancer compared with patients with benign disease (leiomyoma) and those with pre-invasive disease (cervical intraepithelial neoplasia [CIN] I-III) [19]. On the other hand, Choi et al. reported that hyperglycemia did not have an impact on prognosis for patients with cervical cancers [22]. Of concern, all patients included in their study were diagnosed with DM and this disorder was under good control at the time of diagnosis. Moreover, FBG was not considered as a potential covariate and its prognostic effect was not assessed. Therefore, in agreement with the authors’ view, we believe further research is needed.

Previous research has explored the biologic mechanisms linking hyperglycemia with poor cancer outcomes and possible explanations are as follows: First, tumor cells utilize glycolysis instead of mitochondrial oxidative phosphorylation for energy production. In this setting, hyperglycemia provides a high glucose fuel source for cells to maintain rapid proliferation [27, 28]. Second, hyperglycemic conditions can result in enhanced membrane expression of glucose transporters (GLUTs) [28]. Because GLUTs are key mediators responsible for cellular glucose uptake, their overexpression can accelerate the process of glycolysis and increase cancer cell survival [29, 30]. Third, hyperglycemia can activate various signaling pathways and
expression of genes associated with cancer cell proliferation, invasion and migration [26]. Furthermore, the epithelial-mesenchymal transition (EMT) phenotype, a multifaceted process critical for the acquisition of migration, invasiveness and pluripotent stem cell-like behaviors, can be induced by hyperglycemia [31]. Fourth, the high levels of insulin and insulin-like

| Table 3. Cox Proportional Hazards Regression Models of Risk Factors Associated with Recurrence-free Survival. |
|---------------------------------------------------------------|
| **Recurrence-free survival**                                   |
| **Univariate analysis**                                        |
| **HR** | **95% CI** | **P value** | **Univariate analysis** | **HR** | **95% CI** | **P value** | **Multivariate analysis** | **HR** | **95% CI** | **P value** | **Multivariate analysis** | **HR** | **95% CI** | **P value** |
| Age (≥60 vs. <60) | 1.30  | [0.71, 2.40] | 0.392  | 1.46  | [0.79, 2.40] | 0.230  |                      |
| BMI (kg/m²) | 1.06  | [0.91, 1.23] | 0.474  | 1.07  | [0.91, 1.25] | 0.436  |                      |
| Histology (non-squamous vs. squamous) | 2.08  | [1.21, 3.58] | 0.008  | 2.17  | [1.24, 3.79] | 0.007  |                      |
| Tumor stage (IIA2 vs IB2) | 0.92  | [0.57, 1.50] | 0.737  | 1.09  | [0.85, 1.40] | 0.512  |                      |
| Tumor differentiation (G3 vs. G1-2) | 0.66  | [0.29, 1.53] | 0.336  | 0.74  | [0.32, 1.72] | 0.488  |                      |
| Deep stromal invasion (yes vs. no) | 2.25  | [0.97, 5.21] | 0.059  | 2.57  | [1.03, 6.42] | 0.043  |                      |
| LVSI (yes vs. no) | 1.91  | [1.11, 3.28] | 0.020  | 2.01  | [1.14, 3.56] | 0.016  |                      |
| Positive margins (yes vs. no) | 10.70 | [5.76, 19.89] | <0.0001 | 10.37 | [5.45, 19.75] | <0.0001 | 4.80  | [2.51, 9.18] | <0.0001 | 4.95  | [2.50, 9.80] | <0.0001 |
| Positive nodes (yes vs. no) | 7.06  | [3.84, 12.98] | <0.0001 | 7.17  | [3.81, 13.49] | <0.0001 | 4.54  | [2.42, 8.52] | <0.0001 | 4.42  | [2.30, 8.48] | <0.0001 |
| Positive parametrium (yes vs. no) | 8.16  | [4.33, 15.39] | <0.0001 | 7.81  | [4.04, 15.13] | <0.0001 | 3.13  | [1.61, 6.06] | 0.001  | 3.12  | [1.55, 6.28] | 0.001  |
| Adjuvant chemotherapy (yes vs. no) | 0.79  | [0.43, 1.45] | 0.451  | 0.68  | [0.35, 1.31] | 0.248  |                      |
| CR achieved (yes vs. no) | 0.08  | [0.02, 0.34] | 0.001  | 0.09  | [0.02, 0.35] | 0.001  | 0.18  | [0.04, 0.77] | 0.020  | 0.18  | [0.04, 0.74] | 0.018  |
| FBG (>100 mg/dl vs <100 mg/dl) | 1.95  | [1.16, 3.28] | 0.012  | 2.00  | [1.14, 3.50] | 0.015  | 1.69  | [1.00, 2.85] | 0.050  | —    | —    | —    |
| CHO (≥200 mg/dl vs. <200 mg/dl) | 0.86  | [0.53, 1.41] | 0.560  | 0.84  | [0.51, 1.40] | 0.509  |                      |
| TG (≥150 mg/dl vs. <150 mg/dl) | 0.89  | [0.47, 1.66] | 0.703  | 0.82  | [0.42, 1.62] | 0.575  |                      |
| LDL-C (≥130 mg/dl vs. <130 mg/dl) | 0.70  | [0.34, 1.41] | 0.313  | 0.82  | [0.40, 1.66] | 0.574  |                      |
| HDL-C (≥40 mg/dl vs. <40 mg/dl) | 1.45  | [0.66, 3.17] | 0.358  | 1.19  | [0.48, 2.96] | 0.713  |                      |
| SCCA (≥3.5 mg/dl vs. <3.5 mg/dl) | 1.63  | [0.97, 2.73] | 0.067  | 1.60  | [0.93, 2.71] | 0.089  |                      |
| Chemotherapy regimen (Cisplatin + paclitaxel vs. cisplatin-based) | 0.91  | [0.41, 1.96] | 0.805  | 0.99  | [0.45, 2.18] | 0.981  |                      |
| CCRT (yes vs. no) | 4.10  | [1.29, 13.06] | 0.017  | 5.67  | [1.39, 23.21] | 0.016  |                      |

* Patients with diabetes were excluded.

Abbreviation: BMI, body mass index; CCRT, concurrent chemoradiotherapy; CI, confidence interval; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; LVSI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; SCCA, squamous cell carcinoma antigen; TG, triglyceride.

doi:10.1371/journal.pone.0166612.t003
growth factors and chronic inflammatory status of cancer patients with hyperglycemia can inhibit apoptosis and promote metastasis. This finding has been validated by clinical studies [32–35].

Table 4. Cox Proportional Hazards Regression Models of Risk Factors Associated with Cancer-specific Survival.

| Risk Factor                                      | Univariate analysis | Multivariate analysis | Univariate analysis* | Multivariate analysis* |
|-------------------------------------------------|---------------------|-----------------------|----------------------|------------------------|
| Age (<60 vs. <60)                               | 1.40 [0.76, 2.59]   | 1.59 [0.86, 2.90]     | 0.140                |                        |
| BMI (kg/m²)                                     | 1.04 [0.89, 1.21]   | 1.04 [0.88, 1.23]     | 0.656                |                        |
| Histology (non-squamous vs. squamous)           | 2.08 [1.19, 3.64]   | 2.13 [1.20, 3.81]     | 0.010                |                        |
| Tumor stage (IIA2 vs IB2)                       | 1.21 [0.94, 1.55]   | 1.28 [0.98, 1.66]     | 0.071                |                        |
| Tumor differentiation (G3 vs. G1-2)             | 0.77 [0.33, 1.79]   | 0.87 [0.37, 2.02]     | 0.746                |                        |
| Deep stromal invasion (yes vs. no)              | 1.88 [0.85, 4.13]   | 2.07 [0.89, 4.81]     | 0.093                |                        |
| LVI (yes vs. no)                                | 1.72 [0.99, 2.99]   | 1.81 [1.02, 3.23]     | 0.044                |                        |
| Positive margins (yes vs. no)                   | 12.93 [6.80, 24.59] | <0.0001               | 12.78 [6.54, 25.00]  | <0.0001               |
| Positive nodes (yes vs. no)                     | 6.07 [3.34, 11.05]  | <0.0001               | 6.13 [3.30, 11.41]   | <0.0001               |
| Positive parametrium (yes vs. no)               | 10.23 [5.45, 19.22] | <0.0001               | 9.98 [5.16, 19.23]   | <0.0001               |
| Adjuvant chemotherapy (yes vs. no)              | 0.74 [0.39, 1.39]   | 0.351 0.63 [0.32, 1.26] | 0.191                |                        |
| CR achieved (yes vs. no)                        | 0.14 [0.04, 0.43]   | 0.001 0.14 [0.04, 0.45] | 0.011                |                        |
| FBG (>100 mg/dl vs <100mg/dl)                   | 2.24 [1.33, 3.78]   | 2.31 [1.32, 4.03]     | 0.003                | 2.07 [1.22, 3.51]     | 0.007               |
| CHO (>200 mg/dl vs <200 mg/dl)                  | 0.98 [0.59, 1.62]   | 0.942 0.95 [0.56, 1.61] | 0.854                |                        |
| TG (>150 mg/dl vs <150 mg/dl)                   | 1.05 [0.57, 1.93]   | 0.887 1.00 [0.52, 1.94] | 0.994                |                        |
| LDL-C (>130 mg/dl vs <130 mg/dl)                | 0.85 [0.43,1.66]    | 0.626 1.00 [0.50, 1.97] | 0.990                |                        |
| HDL-C (>40 mg/dl vs <40 mg/dl)                  | 1.56 [0.79, 3.43]   | 0.270 1.25 [0.50, 3.13] | 0.635                |                        |
| SCCA (>3.5 mg/dl vs <3.5 mg/dl)                 | 1.83 [1.06, 3.18]   | 0.031 1.84 [1.04, 3.25] | 0.035                |                        |
| Chemotherapy regimen (Cisplatin +paclitaxel vs. cisplatin-based) | 1.43 [0.72, 2.81]   | 0.306 1.58 [0.80, 3.14] | 0.186                |                        |
| CCRT (yes vs. no)                               | 3.04 [1.10, 8.38]   | 0.032 3.69 [1.15, 11.81] | 0.028                |                        |

* Patients with diabetes were excluded.

Abbreviation: BMI, body mass index; CCRT, cocurrent chemoradiotherapy; CI, confidence interval; CR, complete response; CHO, total cholesterol; DM, diabetes mellitus; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; LVI, lymphatic vascular space involvement; NACT, neoadjuvant chemotherapy; SCCA, squamous cell carcinoma antigen; TG, triglyceride.

doi:10.1371/journal.pone.0166612.t004
In the present study, we observed that the rate of CR was significantly lower in hyperglycemic patients (Table 1). Moreover, on multivariable analysis, hyperglycemia is identified as an independent predictor of CR after NACT. In fact, responsiveness to NACT has been noted as the strongest independent prognostic factor for BESCC patients [36]. Additionally, this finding is validated by a meta-analysis where Ye et al. pooled data from 18 studies and reported that the response to NACT was significantly associated with better survival outcomes [37]. The largest study that assessed the long-term benefits of NACT was conducted by Alessandro et al. where 446 patients were included and retrospectively analyzed [38]. Based on long-term follow-up data (median follow-up time: 12.7 years), the authors concluded that response to NACT was a reliable surrogate endpoint of survival for BESCC patients. Differences in the CR rate may be attributed to the poor response to cancer treatments among hyperglycemic

Table 5. Subgroup Analysis of Univariate Hazard Ratios of Survival for Hyperglycemia vs Euglycemia Using the Cox Proportional Hazard Model.

|                      | Recurrence-free survival | Cancer-specific survival |
|----------------------|--------------------------|--------------------------|
|                      | HR          | 95% CI      | P value | HR          | 95% CI      | P value |
| Age                  |             |             |         |             |             |         |
| ≥60                  | 2.49        | [0.82, 7.62] | 0.110   | 2.04        | [0.66, 6.28] | 0.213   |
| <60                  | 1.82        | [1.01, 3.28] | 0.047   | 2.22        | [1.23, 4.01] | 0.008   |
| BMI (kg/m²)          |             |             |         |             |             |         |
| ≥25                  | 1.65        | [0.47, 5.85] | 0.439   | 1.60        | [0.38, 6.71] | 0.523   |
| <25                  | 2.04        | [1.15, 3.61] | 0.015   | 2.40        | [1.37, 4.21] | 0.002   |
| Stage                |             |             |         |             |             |         |
| IB2                  | 3.53        | [1.74, 7.15] | <0.0001 | 3.72        | [1.71, 8.11] | 0.001   |
| IIA2                 | 1.05        | [0.47, 2.31] | 0.913   | 1.43        | [0.70, 2.93] | 0.323   |
| Tumor histology      |             |             |         |             |             |         |
| SCC                  | 2.69        | [1.49, 4.84] | 0.001   | 3.25        | [1.79, 5.91] | <0.0001 |
| NSCC                 | 0.62        | [0.18, 2.18] | 0.459   | 0.58        | [0.16, 2.06] | 0.399   |
| Differentiation      |             |             |         |             |             |         |
| G3                   | 4.63        | [0.93, 22.94] | 0.061   | 4.63        | [0.93, 22.94] | 0.061   |
| G1-2                 | 1.75        | [1.01, 3.05] | 0.047   | 2.06        | [1.18, 3.60] | 0.011   |
| SCCA (ng/ml)         |             |             |         |             |             |         |
| ≥3.5                 | 2.21        | [1.17, 4.18] | 0.014   | 2.40        | [1.28, 4.49] | 0.006   |
| <3.5                 | 1.72        | [0.70, 4.27] | 0.239   | 2.15        | [0.83, 5.55] | 0.114   |
| CHO (mg/dl)          |             |             |         |             |             |         |
| ≥200                 | 1.73        | [0.78, 3.81] | 0.178   | 1.95        | [0.90, 4.23] | 0.090   |
| <200                 | 2.19        | [1.10, 4.36] | 0.026   | 2.50        | [1.23, 5.09] | 0.011   |
| TG (mg/ml)           |             |             |         |             |             |         |
| ≥150                 | 1.31        | [0.39, 4.35] | 0.661   | 1.42        | [0.46, 4.34] | 0.541   |
| <150                 | 2.21        | [1.24, 3.94] | 0.007   | 2.59        | [1.44, 4.69] | 0.002   |
| LDL-C (mg/ml)        |             |             |         |             |             |         |
| ≥130                 | 1.44        | [0.36, 5.75] | 0.608   | 1.87        | [0.53, 6.63] | 0.332   |
| <130                 | 2.13        | [1.21, 3.73] | 0.008   | 2.43        | [1.37, 4.32] | 0.002   |
| HDL-C (mg/ml)        |             |             |         |             |             |         |
| ≥40                  | 1.73        | [0.97, 3.07] | 0.063   | 2.01        | [1.13, 3.57] | 0.017   |
| <40                  | 3.91        | [0.75, 20.27] | 0.105  | 3.69        | [0.72, 19.07] | 0.119   |

Abbreviation: BMI, body mass index; CI, confidence interval; CHO, total cholesterol; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; NSCC, non-squamous cell carcinoma; SCC, squamous cell carcinoma; SCCA, squamous cell carcinoma antigen; TG, triglyceride

doi:10.1371/journal.pone.0166612.t005
patients [39]. Moreover, patients with hyperglycemia frequently have co-morbidities (Table 1). Therefore, their treatment choices may be limited and even clinicians may be less likely to use aggressive treatments, which could be another possible explanation for variations in response rates and survival outcomes according to FBG levels [40, 41].

The major strengths of the present study are: (1) all patients were from a single institution, so uniform treatment principle can be ensured; (2) among studies that evaluate the prognostic role of hyperglycemia for cervical cancer patients, the current one has the largest sample size; (3) we used CSS as the primary study measure instead of overall survival. Accordingly, the possibility that worse prognosis associated with hyperglycemic status can be attributed to the hyperglycemia-related co-morbidities can be eliminated and (4) levels of FBG were measured instead of random blood glucose. Therefore, this value may be used as a baseline parameter for all patients with the same status.

Several limitations of the current study should also be acknowledged. First, due to the retrospective nature, there is unbalanced and unrecognized bias. Second, dosage and period of anti-diabetic drug therapy were not documented in every patient. Accordingly, the potential impact on patient outcome cannot be clarified. Third, our findings may be specific to Chinese populations. Fourth, the proportion of patients with DM was small, which could limit the generalizability of our conclusions from a mixed sample to individual patients with different diabetic status. Finally, for patients with DM, not all clinic notes detailed whether good glycemic control was achieved and the information about treatments for hyperglycemia was not documented for most patients in the HG group. Thus, we could not analyze the survival outcomes for DM patients based on their glycemic control levels. For the same reason, effects of glucose-lowering agents such as metformin on treatment outcomes could not be evaluated. Currently, there is a growing body of evidence that metformin can lower the risk of gynecologic cancers in women with DM [42–44]. A recent meta-analysis also showed that metformin could be a useful adjuvant agent for cancer patients [45]. Given the potential anti-cancer effect, we believe randomized prospective trials are strongly warranted to further investigate metformin activity in gynecological cancers.

Conclusion
In conclusion, our results suggest that FBG ≥ 100 mg/dl is a negative prognostic predictor for BESCC patients treated with NACT. Moreover, patients with hyperglycemia are less likely to achieve CR after NACT. These results underline the clinical utility of hyperglycemia screening, which could help physicians to identify high-risk patients and make individualized therapeutic decisions. A prospective study with adequate sample size is necessary to confirm these findings.

Author Contributions
Conceptualization: JL MFW HWL BZZ LJW ZQL.
Data curation: LJW.
Formal analysis: JL MFW HWL BZZ LJW ZQL.
Investigation: JL MFW HWL BZZ.
Methodology: JL MFW LJW ZQL.
Resources: JL MFW HWL BZZ.
Software: JL.
Supervision: LJW ZQL.

Validation: JL MFW HWL BZZ LJW ZQL.

Visualization: JL MFW HWL BZZ LJW ZQL.

Writing – original draft: JL MFW.

Writing – review & editing: JL MFW HWL BZZ LJW ZQL.

References

1. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, et al. Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN. 2015; 13(4):395–404; quiz PMID: 25870376.

2. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, Fan L, Li J, Chavarri-Guerra Y, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol. 2014; 15(5):489–538. doi: 10.1016/S1470-2045(14)70029-4 PMID: 24731404.

3. Zhao YB, Wang JH, Chen XX, Wu YZ, Wu Q. Values of three different preoperative regimens in comprehensive treatment for young patients with stage Ib2 cervical cancer. Asian Pac J Cancer Prev. 2012; 13(4):1487–9. PMID: 22799353.

4. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, et al. Quality of life and sexual functioning in cervical cancer survivors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(30):7428–36. doi: 10.1200/JCO.2004.00.3996 PMID: 16234510.

5. Singh U, Ahirwar N, Rani AK, Singh N, Sankharw P, Qureshi S. The efficacy and safety of neoadjuvant chemotherapy in treatment of locally advanced carcinoma cervix. J Obstet Gynaecol India. 2013; 63(4):273–8. doi: 10.1007/s13224-012-0342-6 PMID: 24431655; PubMed Central PMCID: PMC3763063.

6. Boronow RC. The bulky 6-cm barrel-shaped lesion of the cervix: primary surgery and postoperative chemoradiation. Gynecologic oncology. 2000; 78(3 Pt 1):313–7. doi: 10.1006/gy no.2000.5911 PMID: 10985886.

7. Hacker NF, Wain GV, Nicklin JL. Resection of bulky positive lymph nodes in patients with cervical carcinoma. International journal of gynecologic cancer: official journal of the International Gynecologic Cancer Society. 1995; 5(4):250–6. PMID: 11578485.

8. Kupets R, Thomas GM, Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer? Gynecologic oncology. 2002; 87(2):163–70. PMID: 12477446.

9. Hu T, Li S, Chen Y, Shen J, Li X, Huang K, et al. Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IB2 cervical cancer to establish selection criteria. European journal of cancer. 2012; 48(15):2353–60. doi: 10.1016/j.ejca.2012.03.015 PMID: 22503395.

10. Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH. Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGCG-1005). International journal of gynecologic cancer: official journal of the International Gynecologic Cancer Society. 2007; 17(1):132–6. doi: 10.1111/j.1525-1438.2007.00803.x PMID: 17291243.

11. Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, et al. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British journal of cancer. 2013; 108(2):380–6. doi: 10.1038/bjc.2012.566 PMID: 23299534; PubMed Central PMCID: PMC3566812.

12. Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung cancer. 2012; 76(2):242–7. doi: 10.1016/j.lungcan.2011.10.019 PMID: 22112292.

13. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Annals of surgical oncology. 2010; 17(2):502–13. doi: 10.1245/s10434-009-0789-6 PMID: 19856977.

14. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(1):54–60. doi: 10.1200/JCO.2010.31.183 PMID: 21115861; PubMed Central PMCID: PMC3055860.

15. Kiderlen M, de Glis NA, Bastiaannet E, Engels CC, van de Water W, de Craen AJ, et al. Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2013; 24(12):3011–6. doi: 10.1093/annonc/mdt367 PMID: 24026538.
16. Sonabend RY, McKay SV, Okcu MF, Yan J, Raymond MW, Margolin JF. Hyperglycemia during induction therapy is associated with poorer survival in children with acute lymphocytic leukemia. The Journal of pediatrics. 2009; 155(1):73–8. doi: 10.1016/j.jpeds.2009.01.072 PMID: 19394046.

17. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(3):433–40. PMID: 12560431. doi: 10.1200/JCO.2003.07.125.

18. Lee YY, Choi CH, Kim CJ, Song TJ, Kim MK, Kim TJ, et al. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA). Gynecologic oncology. 2010; 116(3):459–63. doi: 10.1016/j.ygyno.2009.11.016 PMID: 20004008.

19. Nomelini RS, Neto AS, Capuci KA, Murta BM, Murta EF. Relationship between plasma glucose levels and malignant uterine cervical neoplasias. Clinical Medicine Insights Oncology. 2011; 5:77–82. doi: 10.4137/CMO.S6916 PMID: 21603242; PubMed Central PMCID: PMC3095023.

20. Lamkin DM, Spitz DR, Shahzad MM, Lenihan DJ, Degeest K, et al. Glucose as a prognostic factor in ovarian carcinoma. Cancer. 2009; 115(7):1915–61. doi: 10.1002/cncr.24126 PMID: 19156916; PubMed Central PMCID: PMC2649990.

21. Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. Journal of neuro-oncology. 2015; 124(1):119–26. doi: 10.1007/s11060-015-1815-0 PMID: 26015297; PubMed Central PMCID: PMC4498235.

22. In Choi J, Chang HK, Lee DW, Lee KH, Park JS, Lee HN. Does diabetes mellitus have an impact on the prognosis for patients with cervical cancer? Gynecologic oncology. 2015; 139(2):319–23. doi: 10.1016/j.ygyno.2015.09.004 PMID: 26360017.

23. Takatori E, Shoji T, Omi H, Kagabu M, Miura F, Takeuchi S, et al. Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy. International journal of clinical oncology. 2015; 20(2):345–50. doi: 10.1007/s10147-014-0702-6 PMID: 24825458.

24. Joint Committee for Developing Chinese guidelines on P, Treatment of Dyslipidemia in A. [Chinese guidelines on prevention and treatment of dyslipidemia in adults]. Zhonghua xin xue guan bing za zhi. 2007; 35(5):390–419. PMID: 17711682.

25. Li X, Zhou J, Huang K, Tang F, Wang S, et al. The predictive value of serum squamous cell carcinoma antigen in patients with cervical cancer who receive neoadjuvant chemotheraphy followed by radical surgery: a single-institute study. PloS one. 2015; 10(4):e0122361. doi: 10.1371/journal.pone.0122361 PMID: 25860888; PubMed Central PMCID: PMC4393273.

26. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes care. 2008; 31 Suppl 1:S55–60. doi: 10.2337/dc08-S055 PMID: 18165338.

27. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309–14. PMID: 13298683.

28. Ryu TY, Park J, Scherer PE. Hyperglycemia as a risk factor for cancer progression. Diabetes & metabolism journal. 2014; 38(5):330–6. doi: 10.4093/dmj.2014.38.5.330 PMID: 25349819; PubMed Central PMCID: PMC4209346.

29. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Molecular aspects of medicine. 2013; 34(2–3):121–38. doi: 10.1007/978-3-642-36751-1_8 PMID: 24104978.

30. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biological research. 2002; 35(1):9–26. PMID: 12125211.

31. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer cell. 2013; 23(3):316–31. doi: 10.1016/j.ccr.2013.01.022 PMID: 23453623; PubMed Central PMCID: PMC3703516.

32. Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciaccia L, et al. Insulin receptors in breast cancer. Annals of the New York Academy of Sciences. 1996; 764:173–88. PMID: 8651567.

33. Papa V, Belfiore A. Insulin receptors in breast cancer: biological and clinical role. Journal of endocrinological investigation. 1996; 19(5):324–33. doi: 10.1007/BF03347871 PMID: 8796343.

34. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proceedings of the Association of American Physicians. 1997; 109(6):565–71. PMID: 9394418.

35. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madamann Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002; 20(1):42–51. PMID: 11773152. doi: 10.1200/JCO.2002.20.1.42
36. Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, et al. Pathologic response on surgical samples is an independent prognostic variable for patients with Stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: an Italian multicenter retrospective study (CTF Study). Gynecologic oncology. 2013; 131(3):640–4. doi: 10.1016/j.ygyno.2013.09.029 PMID: 24096111.

37. Ye Q, Yuan HX, Chen HL. Responsiveness of neoadjuvant chemotherapy before surgery predicts favorable prognosis for cervical cancer patients: a meta-analysis. Journal of cancer research and clinical oncology. 2013; 139(11):1887–98. doi: 10.1007/s00432-013-1509-y PMID: 24022086.

38. Buda A, Lissoni AA, Floriani I, Biagioli E, Gerardi C, Bonazzi C, et al. Long-Term Clinical Benefits of Neoadjuvant Chemotherapy in Women With Locally Advanced Cervical Cancer: Validity of Pathological Response as Surrogate Endpoint of Survival. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2015; 25(8):1468–75. doi: 10.1097/IGC.0000000000000515 PMID: 26222484.

39. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American journal of clinical oncology. 2011; 34(3):292–6. doi: 10.1097/COC.0b013e3181e1d0c0 PMID: 20622641.

40. Satariano WA. Comorbidity and functional status in older women with breast cancer: implications for screening, treatment, and prognosis. Journal of gerontology. 1992; 47 Spec No:24–31. PMID: 1430879.

41. Srokowski TP, Fang S, Hortobagyi GN, Giordano SH. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. Journal of clinical oncology; official journal of the American Society of Clinical Oncology. 2009; 27(13):2170–6. doi: 10.1200/JCO.2008.17.595 PMID: 19307509; PubMed Central PMCID: PMC2674004.

42. Tseng CH. Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget. 2016. Epub 2016/08/04. doi: 10.18632/oncotarget.10934 PMID: 27486978.

43. Gadducci A, Biglia N, Tana R, Cosio S, Gallo M. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. Critical reviews in oncology/hematology. 2016; 105:73–83. Epub 2016/07/06. doi: 10.1016/j.critrevonc.2016.06.006 PMID: 27378194.

44. Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes/metabolism research and reviews. 2015; 31(6):619–26. Epub 2015/03/31. doi: 10.1002/dmrr.2649 PMID: 25820555.

45. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2016. Epub 2016/09/30. doi: 10.1093/annonc/mdw410 PMID: 27681864.